Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition - PubMed (original) (raw)
. 2007 Oct 5;282(40):29241-7.
doi: 10.1074/jbc.M704587200. Epub 2007 Aug 6.
Affiliations
- PMID: 17684013
- DOI: 10.1074/jbc.M704587200
Free article
Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition
Bert J C Janssen et al. J Biol Chem. 2007.
Free article
Abstract
Undesired complement activation is a major cause of tissue injury in various pathological conditions and contributes to several immune complex diseases. Compstatin, a 13-residue peptide, is an effective inhibitor of the activation of complement component C3 and thus blocks a central and crucial step in the complement cascade. The precise binding site on C3, the structure in the bound form, and the exact mode of action of compstatin are unknown. Here we present the crystal structure of compstatin in complex with C3c, a major proteolytic fragment of C3. The structure reveals that the compstatin-binding site is formed by the macroglobulin (MG) domains 4 and 5. This binding site is part of the structurally stable MG-ring formed by domains MG 1-6 and is far away from any other known binding site on C3. Compstatin does not alter the conformation of C3c, whereas compstatin itself undergoes a large conformational change upon binding. We propose a model in which compstatin sterically hinders the access of the substrate C3 to the convertase complexes, thus blocking complement activation and amplification. These insights are instrumental for further development of compstatin as a potential therapeutic.
Similar articles
- Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.
Sahu A, Soulika AM, Morikis D, Spruce L, Moore WT, Lambris JD. Sahu A, et al. J Immunol. 2000 Sep 1;165(5):2491-9. doi: 10.4049/jimmunol.165.5.2491. J Immunol. 2000. PMID: 10946275 - Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts.
Fiane AE, Mollnes TE, Videm V, Hovig T, Høgåsen K, Mellbye OJ, Spruce L, Moore WT, Sahu A, Lambris JD. Fiane AE, et al. Xenotransplantation. 1999 Feb;6(1):52-65. doi: 10.1034/j.1399-3089.1999.00007.x. Xenotransplantation. 1999. PMID: 10355733 - Compstatin: a complement inhibitor on its way to clinical application.
Ricklin D, Lambris JD. Ricklin D, et al. Adv Exp Med Biol. 2008;632:273-92. doi: 10.1007/978-0-387-78952-1_20. Adv Exp Med Biol. 2008. PMID: 19025129 Free PMC article. Review. - Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.
Soulika AM, Holland MC, Sfyroera G, Sahu A, Lambris JD. Soulika AM, et al. Mol Immunol. 2006 May;43(12):2023-9. doi: 10.1016/j.molimm.2005.12.002. Epub 2006 Feb 10. Mol Immunol. 2006. PMID: 16472861 - Structural aspects and design of low-molecular-mass complement inhibitors.
Morikis D, Lambris JD. Morikis D, et al. Biochem Soc Trans. 2002 Nov;30(Pt 6):1026-36. doi: 10.1042/bst0301026. Biochem Soc Trans. 2002. PMID: 12440966 Review.
Cited by
- Inhibiting alternative pathway complement activation by targeting the factor D exosite.
Katschke KJ Jr, Wu P, Ganesan R, Kelley RF, Mathieu MA, Hass PE, Murray J, Kirchhofer D, Wiesmann C, van Lookeren Campagne M. Katschke KJ Jr, et al. J Biol Chem. 2012 Apr 13;287(16):12886-92. doi: 10.1074/jbc.M112.345082. Epub 2012 Feb 23. J Biol Chem. 2012. PMID: 22362762 Free PMC article. - Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways.
Sonnentag SJ, Dopler A, Kleiner K, Garg BK, Mannes M, Späth N, Akilah A, Höchsmann B, Schrezenmeier H, Anliker M, Boyanapalli R, Huber-Lang M, Schmidt CQ. Sonnentag SJ, et al. J Biol Chem. 2024 Apr;300(4):105784. doi: 10.1016/j.jbc.2024.105784. Epub 2024 Feb 23. J Biol Chem. 2024. PMID: 38401844 Free PMC article. - Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.
Zwarthoff SA, Berends ETM, Mol S, Ruyken M, Aerts PC, Józsi M, de Haas CJC, Rooijakkers SHM, Gorham RD Jr. Zwarthoff SA, et al. Front Immunol. 2018 Jul 23;9:1691. doi: 10.3389/fimmu.2018.01691. eCollection 2018. Front Immunol. 2018. PMID: 30083158 Free PMC article. - Insights from molecular dynamics simulations for computational protein design.
Childers MC, Daggett V. Childers MC, et al. Mol Syst Des Eng. 2017 Feb 1;2(1):9-33. doi: 10.1039/C6ME00083E. Epub 2017 Jan 9. Mol Syst Des Eng. 2017. PMID: 28239489 Free PMC article. - Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.
DeAngelis RA, Reis ES, Ricklin D, Lambris JD. DeAngelis RA, et al. Immunobiology. 2012 Nov;217(11):1097-105. doi: 10.1016/j.imbio.2012.07.012. Immunobiology. 2012. PMID: 22964235 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Miscellaneous